Skip to content
eventVerified

WHO 2015 Essential Medicines List adds sofosbuvir and daclatasvir for hepatitis C

Dated 8 May 2015: WHO 2015 Essential Medicines List adds sofosbuvir and daclatasvir for hepatitis C. In the causal graph this event strengthens Access to Essential Medicines, a driver that weakens Proportion of the population with positive out-of-pocket household expenditure on health exceeding 40% of household discretionary budget, by location, quintile, type of household and characteristics of the head of household (%) — an improving welfare path.

Who was responsible

Contribution type and responsibility level for each recorded actor — not sole-author shorthand.

No public contributors are listed for this fact.

What changed

Fact → Driver → Indicator. Relationship strength orders the paths; it is not the observed indicator movement.

Causal path

How this event connects to drivers and indicators in the graph.

  1. FactWHO 2015 Essential Medicines List adds sofosbuvir and daclatasvir for hepatitis C
  2. strengthensDriverAccess to Essential Medicines
  3. weakensIndicatorProportion of the population with positive out-of-pocket household expenditure on health exceeding 40% of household discretionary budget, by location, quintile, type of household and characteristics of the head of household (%)

Cite this page

Factrail. (2026). WHO 2015 Essential Medicines List adds sofosbuvir and daclatasvir for hepatitis C. Factrail. https://factrail.ai/facts/who-eml-2015-hepatitis-c-sofosbuvir-daclatasvir

https://factrail.ai/facts/who-eml-2015-hepatitis-c-sofosbuvir-daclatasvir

Accessed 16 October 2026.

By the · Method: how we source and score · Last reviewed

Dispute this factNamed here, or represent someone who is? Request a right of reply.